Scientists Identify New Immunotherapy Target for Pediatric Cancers – Genetic Engineering & Biotechnology News (press release)
Drug Target Review |
Scientists Identify New Immunotherapy Target for Pediatric Cancers
Genetic Engineering & Biotechnology News (press release) Scientists in the U.S. and Canada have identified a key immunotherapy target for high-risk neuroblastoma and other childhood cancers, and developed an antibody-drug conjugate (ADC) targeting the cell surface co-receptor, glypican 2 (GLP2), which … Cell surface protein may offer target in treating childhood cancersDrug Target Review |
|
Benson Hill Biosystems Launches Novel Genome Editing CRISPR …
Newswise (press release) Newswise — ST. LOUIS, MO.—September 12, 2017—Benson Hill Biosystems, an agricultural technology company that uses cloud biology to unlock the genetic … |
|
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type …
Nasdaq The initiation of this natural history study brings us one step closer to our goal of making a CRISPR-based medicine available to people with significant vision loss caused by LCA10,” said Gerry Cox, M.D., Ph.D., Chief Medical Officer, Editas Medicine. |
|
Swedish Study Suggests Stem Cell Transplants as Possible Treatment for Aggressive RRMS
Multiple Sclerosis News Today In addition, says the review, the procedure’s safety profile has improved in the last decade, and is now just as good as approved medications. This data supports the idea that bone marrow stem cell transplants could be recommended for RRMS patients who … |
Scientific American |
Powerful Childhood Cancer Treatment Holds Promise–and Poses Hazards
Scientific American It is the first in a novel class of treatments known as CAR-Ts—for chimeric antigen receptor T cells—in which a patient’s own immune cells are withdrawn, engineered to target cancer cells, and then infused back into the body. “CAR–T cells are going … |